JP2020517619A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517619A5 JP2020517619A5 JP2019556654A JP2019556654A JP2020517619A5 JP 2020517619 A5 JP2020517619 A5 JP 2020517619A5 JP 2019556654 A JP2019556654 A JP 2019556654A JP 2019556654 A JP2019556654 A JP 2019556654A JP 2020517619 A5 JP2020517619 A5 JP 2020517619A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- salt
- compound according
- pharmaceutical composition
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 125000004122 cyclic group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 239000003085 diluting agent Substances 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 230000008728 vascular permeability Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17167549 | 2017-04-21 | ||
| EP17167549.9 | 2017-04-21 | ||
| PCT/EP2018/059633 WO2018192866A1 (en) | 2017-04-21 | 2018-04-16 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517619A JP2020517619A (ja) | 2020-06-18 |
| JP2020517619A5 true JP2020517619A5 (enExample) | 2021-05-27 |
| JP7175914B2 JP7175914B2 (ja) | 2022-11-21 |
Family
ID=58606127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556654A Active JP7175914B2 (ja) | 2017-04-21 | 2018-04-16 | 血漿カリクレイン阻害剤としてのヘテロアリールカルボキサミド誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10501440B2 (enExample) |
| EP (1) | EP3612523B1 (enExample) |
| JP (1) | JP7175914B2 (enExample) |
| CN (1) | CN110546146B (enExample) |
| AR (1) | AR111414A1 (enExample) |
| TW (1) | TW201902887A (enExample) |
| WO (1) | WO2018192866A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112839711A (zh) | 2018-10-10 | 2021-05-25 | 勃林格殷格翰国际有限公司 | 作为血浆激肽释放酶抑制剂的苯基四唑衍生物 |
| TW202144331A (zh) | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| TW202535863A (zh) | 2020-02-13 | 2025-09-16 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| WO2021198534A1 (en) | 2020-04-04 | 2021-10-07 | Oxurion NV | Plasma kallikrein inhibitors for use in the treatment of coronaviral disease |
| AU2021306250A1 (en) * | 2020-07-10 | 2023-02-16 | Merck Sharp & Dohme Llc | Plasma kallikrein inhibitors |
| WO2023144030A1 (en) | 2022-01-31 | 2023-08-03 | Oxurion NV | Plasma kallikrein inhibitor therapy for anti-vegf sensitization |
| WO2023148016A1 (en) | 2022-02-04 | 2023-08-10 | Oxurion NV | Biomarker for plasma kallikrein inhibitor therapy response |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2734462B1 (de) | 2011-07-21 | 2019-03-20 | ThyssenKrupp System Engineering GmbH | Vorrichtung und verfahren zum stoppen und/oder ausrichten von transportgütern auf einer fördereinrichtung und fördereinrichtung |
| US20140378474A1 (en) | 2012-01-27 | 2014-12-25 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| CN105452240B (zh) | 2013-05-23 | 2018-06-26 | 卡尔维斯塔制药有限公司 | 杂环衍生物 |
| US10640486B2 (en) | 2015-10-27 | 2020-05-05 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
-
2018
- 2018-04-16 US US15/953,523 patent/US10501440B2/en active Active
- 2018-04-16 JP JP2019556654A patent/JP7175914B2/ja active Active
- 2018-04-16 CN CN201880026013.2A patent/CN110546146B/zh active Active
- 2018-04-16 WO PCT/EP2018/059633 patent/WO2018192866A1/en not_active Ceased
- 2018-04-16 EP EP18719794.2A patent/EP3612523B1/en active Active
- 2018-04-20 AR ARP180101024A patent/AR111414A1/es unknown
- 2018-04-20 TW TW107113453A patent/TW201902887A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517619A5 (enExample) | ||
| JP2019094345A5 (enExample) | ||
| JP2018536648A5 (enExample) | ||
| JP2018535963A5 (enExample) | ||
| JP2019031560A5 (enExample) | ||
| JP2016508506A5 (enExample) | ||
| JP2014521688A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2011137006A5 (enExample) | ||
| JP2016505637A5 (enExample) | ||
| JP2016517417A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| JP2009526830A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| JP2004506736A5 (enExample) | ||
| JP2009513703A5 (enExample) | ||
| JP2014518853A5 (enExample) | ||
| JP2011519360A5 (enExample) | ||
| JP2014502988A5 (enExample) | ||
| JP2017538689A5 (enExample) | ||
| JP2007502295A5 (enExample) | ||
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий |